Regeneron(REGN) - 2024 Q4 - Annual Results

Exhibit 99.1 Press Release Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43 Annual J.P. Morgan Healthcare Conference Dupixent is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD and EYLEA remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudi ...